Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 10/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13370752 | 0.79 | TGFBR1 (0.43) | RAB9ANPC1CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL29374931 | 0.76 | RAB9A (0.64) | RAB9ANPC1CYP1A2CYP3A4AR | |
| SCHEMBL170196 | 0.76 | RAB9A (0.64) | RAB9ANPC1CYP1A2CYP3A4AR | |
| SCHEMBL1327331 | 0.76 | RAB9A (0.50) | RAB9ANPC1CYP1A2CYP3A4AR | |
| SCHEMBL713066 | 0.76 | NPC1 (0.47) | RAB9ANPC1CYP1A2MEN1KMT2A | |
| SCHEMBL713792 | 0.75 | ALDH1A1 (0.41) | CYP3A4CYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL3146084 | 0.74 | KDM4E (0.41) | RAB9ANPC1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL3889478 | 0.74 | RAB9A (0.41) | RAB9ANPC1CYP1A2CYP3A4AR | |
| SCHEMBL715296 | 0.74 | LMNA (0.52) | CYP3A4CYP2D6MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL31243061 | 0.74 | ALDH1A1 (0.63) | RAB9ANPC1CYP1A2CYP3A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263912-A | Azanaphthyl substituted electricity-absorbing fragment compound and application thereof | 烟台显华科技集团股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| US-20230220161-A1 | POLYIMIDE PRECURSOR PREPARED BY USING POLYCYCLIC MONOMER INCLUDING TRIFLUOROMETHYL GROUP AND FLEXIBLE POLYIMIDE OBTAINED BY USING THE SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-07-13 | — | — | US | claimed |
| CN-110540527-B | Novel triphenylene compound and organic light-emitting device using same | 株式会社LG化学 | 2023-04-07 | — | — | CN | claimed |
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | claimed |
| CN-111316459-A | Photoelectric conversion element and imaging device | 索尼公司 | 2020-06-19 | — | — | CN | claimed |
| US-10566548-B2 | Image sensor, stacked imaging device and imaging module | SONY CORPORATION (JP) | 2020-02-18 | — | — | US | claimed |
| EP-3300114-B1 | IMAGING ELEMENT, MULTILAYER IMAGING ELEMENT AND IMAGING DEVICE | SONY CORP (JP) | 2020-01-08 | — | — | EP | claimed |
| CN-110540527-A | Novel triphenylene compound and organic light-emitting device using same | LG CHEMICAL LTD | 2019-12-06 | — | — | CN | claimed |
| US-20180114926-A1 | IMAGE SENSOR, STACKED IMAGING DEVICE AND IMAGING MODULE | SONY CORPORATION (JP) | 2018-04-26 | — | — | US | claimed |
| EP-3300114-A1 | IMAGING ELEMENT, MULTILAYER IMAGING ELEMENT AND IMAGING DEVICE | Sony Corporation (JP) | 2018-03-28 | — | — | EP | claimed |
| JP-2007501804-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1673357-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-28 | — | — | EP | claimed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | claimed |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | claimed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | claimed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | claimed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | claimed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | claimed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | claimed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | RAB9A 1749/4885NPC1 487/4885CYP1A2 4265/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | RAB9A 1749/4885NPC1 487/4885CYP1A2 4265/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | RAB9A 1092/4885NPC1 875/4885CYP1A2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.